Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blackpoint Oral Spray is a metered-dose delivery device (MDD) designed for the sublingual administration of pharmaceutical-grade tetrahydrocannabinol (THC). Developed by Blackpoint Biotech, the device delivers a precise 5mg dose of THC per spray in a fine aerosolized mist, facilitating rapid absorption through the oral mucosa and bypassing first-pass metabolism in the digestive system. The formulation contains 100 doses (500mg total THC) and is naturally flavored with plant-based terpenes such as limonene. It is manufactured according to EU GMP standards to provide medical cannabis patients with a reliable, repeatable, and discreet delivery method for controlled cannabinoid dosing without the need for inhalation of smoke.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Blackpoint Oral Spray.